1. Home
  2. TULP vs FEMY Comparison

TULP vs FEMY Comparison

Compare TULP & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bloomia Holdings Inc. Common Stock

TULP

Bloomia Holdings Inc. Common Stock

SELL

Current Price

$2.31

Market Cap

12.0M

ML Signal

SELL

Logo Femasys Inc.

FEMY

Femasys Inc.

SELL

Current Price

$1.22

Market Cap

11.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TULP
FEMY
Founded
1990
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Medical/Dental Instruments
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
11.5M
IPO Year
2026
2021

Fundamental Metrics

Financial Performance
Metric
TULP
FEMY
Price
$2.31
$1.22
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $14.75
AVG Volume (30 Days)
4.4K
★ 104.8K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 44.71
EPS
★ N/A
N/A
Revenue
★ $18,800,000.00
$2,293,313.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$294.61
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 40.77
52 Week Low
$2.00
$0.29
52 Week High
$4.99
$6.29

Technical Indicators

Market Signals
Indicator
TULP
FEMY
Relative Strength Index (RSI) 42.34 36.99
Support Level $2.00 $0.33
Resistance Level $2.50 $1.55
Average True Range (ATR) 0.14 0.14
MACD 0.05 0.01
Stochastic Oscillator 53.09 36.46

Price Performance

Historical Comparison
TULP
FEMY

About TULP Bloomia Holdings Inc. Common Stock

Bloomia Holdings Inc is a specialty agricultural company focused on making and managing its ag investments in the U.S. and internationally. The Company is the majority owner of Bloomia, one of the largest producers of fresh-cut tulips in the United States.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: